



PARKINSON'S DISEASE NEWS

<http://www.viartis.net/parkinsons.disease/news.htm>

24th March 2103 - News release

NEW L-DOPA PRODUCT EXCEEDS THE EFFECT OF STALEVO

A new L-dopa product, which is presently called ODM-101, significantly decreased daily OFF-time without increasing ON-time with troublesome dyskinesias when compared to Stalevo, which is a standard medication in advanced Parkinson's Disease when people experience end-of-dose wearing off symptoms using L-dopa.

Stalevo contains three active substances in one tablet : L-dopa, plus carbidopa and entacapone, both of which help to maintain L-dopa levels. For more information go to Stalevo.

<http://www.stalevo.com/info/about/parkinsons-disease.jsp>

ODM-101 has the same components as Stalevo but has a higher and fixed amount of carbidopa (either 65mg or 105 mg) regardless of the L-dopa dosage. As it made by the same manufacturers it is effectively an improved form of Stalevo.

People with Parkinson's Disease were given two forms of ODM-101 with two different amounts of carbidopa : ODM-101/65mg and ODM-101/105mg. Both of them reduced daily OFF-time more than Stalevo. ODM-101/105mg was marginally better than ODM-101/65mg. Similarly, both ODM-101 combinations increased the ON-time without troublesome dyskinesia significantly more than Stalevo. There were no significant differences between the treatments in ON-time with troublesome dyskinesia or in UPDRS II and III symptom scores. Overall, tolerability and safety of ODM-101 was comparable to that of Stalevo. For more information go to the News release.

<http://www.orion.fi/en/News-and-media/Press-releases2/Archive/2013/3/>

<http://www.viartis.net/parkinsons.disease/news/130324.pdf>

mail@viartis.net

©2013 Viartis